Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies

[1]  P. Barter,et al.  Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial , 2018, Circulation.

[2]  J. Nelson,et al.  ApoA1 Remnant Ratio in Very High Risk Patients with LDL-c 55 Years of Age , 2018 .

[3]  S. Martin,et al.  Effect of Evolocumab on Lipoprotein Particles. , 2018, The American journal of cardiology.

[4]  Lawrence A Leiter,et al.  Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. , 2017, The lancet. Diabetes & endocrinology.

[5]  P. Ridker,et al.  Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Very‐Low‐Density Lipoproteins , 2017, Journal of the American Heart Association.

[6]  Marc P. Bonaca,et al.  Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) , 2017, Circulation.

[7]  N. Wong.  Residual Risk After Treatment of Patients With Atherosclerotic Cardiovascular Disease With Proprotein Convertase Subtilisin-Kexin Type 9 Monoclonal Antibody Therapy (from the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Trial). , 2017, The American journal of cardiology.

[8]  E. Stroes,et al.  How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL. , 2017, Atherosclerosis. Supplements.

[9]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[10]  B. Horne,et al.  The utility of the apolipoprotein A1 remnant ratio in predicting incidence coronary heart disease in a primary prevention cohort: The Jackson Heart Study , 2016, European journal of preventive cardiology.

[11]  R. D'Agostino,et al.  Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies , 2016, Journal of the American Heart Association.

[12]  Jennifer G. Robinson,et al.  CLINICAL EQUIVALENCE OF EVOLOCUMAB AMONG PATIENT SUBGROUPS IN PROFICIO: A POOLED ANALYSIS OF 3146 PATIENTS FROM PHASE 3 STUDIES , 2015 .

[13]  M. Emery,et al.  Evolocumab (AMG 145) for primary hypercholesterolemia , 2015, Expert review of cardiovascular therapy.

[14]  Lesley Burgess,et al.  PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[15]  Z. Awan,et al.  Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia. , 2014, Clinical chemistry.

[16]  P. Toth,et al.  Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. , 2014, Atherosclerosis.

[17]  H. Bays,et al.  Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. , 2014, Journal of the American College of Cardiology.

[18]  Jennifer G. Robinson,et al.  Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. , 2014, JAMA.

[19]  C. Ballantyne,et al.  A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. , 2014, The New England journal of medicine.

[20]  B. Nordestgaard,et al.  Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. , 2014, Pharmacology & therapeutics.

[21]  A. Gotto,et al.  Residual macrovascular risk in 2013: what have we learned? , 2014, Cardiovascular Diabetology.

[22]  B. Nordestgaard,et al.  Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation , 2013, Circulation.

[23]  A. Prat,et al.  Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1) , 2013, PloS one.

[24]  B. Horne,et al.  A new ratio for better predicting future death/myocardial infarction than standard lipid measurements in women >50 years undergoing coronary angiography: the apolipoprotein A1 remnant ratio (Apo A1/ [VLDL3+IDL]) , 2013, Lipids in Health and Disease.

[25]  B. Nordestgaard,et al.  Remnant cholesterol as a causal risk factor for ischemic heart disease. , 2013, Journal of the American College of Cardiology.

[26]  M. Gnant,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .

[27]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[28]  Yan Wang,et al.  A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates , 2009, Proceedings of the National Academy of Sciences.

[29]  A. Prat,et al.  The Proprotein Convertase PCSK9 Induces the Degradation of Low Density Lipoprotein Receptor (LDLR) and Its Closest Family Members VLDLR and ApoER2* , 2008, Journal of Biological Chemistry.

[30]  I. Holme,et al.  High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study☆ , 2002 .

[31]  S. Devaraj,et al.  Remnant lipoproteins: measurement and clinical significance. , 2002, Clinical chemistry.

[32]  I. Holme,et al.  High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study , 2001, The Lancet.

[33]  D. A. Chappell,et al.  Receptor-mediated mechanisms of lipoprotein remnant catabolism. , 1998, Progress in lipid research.

[34]  A. Cooper.  Hepatic uptake of chylomicron remnants. , 1997, Journal of lipid research.

[35]  Sadao Takahashi,et al.  Enhancement of the Binding of Triglyceride-rich Lipoproteins to the Very Low Density Lipoprotein Receptor by Apolipoprotein E and Lipoprotein Lipase (*) , 1995, The Journal of Biological Chemistry.

[36]  C. E. Becker.  The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. , 1984, JAMA.

[37]  The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. , 1984, JAMA.